clinical trial · NCT05757869
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Janssen Research & Development, LLC·phase3·active not recruiting·n = 20,284
Atrial FibrillationMilvexianApixabanPlaceboApixaban Placebo
brief summary
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
started
Apr 11, 2023
primary completion
Oct 31, 2026
completion
Oct 31, 2026
last updated
Jul 6, 2026
official title
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol